| Glaucoma, Open-Angle
Alphagan P vs Xalatan
Side-by-side clinical, coverage, and cost comparison for glaucoma, open-angle.Deep comparison between: Alphagan P vs Xalatan with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXalatan has a higher rate of injection site reactions vs Alphagan P based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xalatan but not Alphagan P, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Alphagan P
Xalatan
At A Glance
Ophthalmic
Three times daily
Alpha-2 adrenergic receptor agonist
Ophthalmic
Once daily
Prostaglandin F2-alpha analogue
Indications
- Glaucoma, Open-Angle
- Ocular Hypertension
- Glaucoma, Open-Angle
- Ocular Hypertension
Dosing
Glaucoma, Open-Angle, Ocular Hypertension One drop in the affected eye(s) three times daily, approximately 8 hours apart; if used with other topical ophthalmic products, instill at least 5 minutes apart.
Glaucoma, Open-Angle, Ocular Hypertension One drop in the affected eye(s) once daily in the evening; do not exceed once daily dosing.
Contraindications
- Neonates and infants (pediatric patients younger than 2 years old)
- Previous hypersensitivity reaction to any component of ALPHAGAN P
- Known hypersensitivity to latanoprost, benzalkonium chloride, or any other ingredients in this product
Adverse Reactions
Most common (>=10%) Allergic conjunctivitis, conjunctival hyperemia, eye pruritus
Serious Potentiation of vascular insufficiency, severe cardiovascular disease
Postmarketing Bradycardia, depression, hypersensitivity, iritis, keratoconjunctivitis sicca, miosis, nausea, skin reactions, syncope, tachycardia
Most common (5-15%) Foreign body sensation, punctate keratitis, stinging, conjunctival hyperemia, blurred vision, itching, burning, increased pigmentation of the iris
Serious Iris pigmentation changes, eyelid skin darkening, eyelash changes, intraocular inflammation (iritis/uveitis), macular edema including cystoid macular edema
Postmarketing Dizziness, headache, toxic epidermal necrolysis, keratitis, corneal edema and erosions, trichiasis, iris cyst, conjunctivitis, pseudopemphigoid of the ocular conjunctiva, asthma, dyspnea, nausea, vomiting, pruritis, herpes keratitis, angina, palpitations, chest pain
Pharmacology
Brimonidine tartrate is a relatively selective alpha-2 adrenergic receptor agonist that lowers intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow, with a peak ocular hypotensive effect at approximately 2 hours post-dosing.
Latanoprost is a prostaglandin F2-alpha analogue that reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Alphagan P
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
Xalatan
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Alphagan P
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Xalatan
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Alphagan P
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (3/3) · Qty limit (0/3)
Xalatan
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Alphagan P.
No savings programs available for Xalatan.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Alphagan PView full Alphagan P profile
XalatanView full Xalatan profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.